A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

NCT06390774 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

DRUG: SSGJ-705

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.